Streetbeat News

HRMY

Harmony Biosciences Holdings, Inc.

https://www.harmonybiosciences.com

Industry

Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Open

33.00

Mkt cap

1.9B

Volume

328K

High

33.18

P/E Ratio

15.56

52-wk high

41.61

Low

32.42

Div yield

N/A

52-wk low

27.14

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. for potential securities fraud. This follows a report by Scorpion Capital raising concerns about Harmony's narcolepsy drug, Wakix.

Portfolio Pulse from

November 08, 2024 | 12:45 pm

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. for potential violations of federal securities laws, following a report by Scorpion Capital raising concerns about its narcolepsy drug, Wakix.

Portfolio Pulse from

November 07, 2024 | 12:45 pm

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. for potential violations of federal securities laws, following a report by Scorpion Capital raising concerns about Harmony's narcolepsy drug, Wakix.

Portfolio Pulse from

November 06, 2024 | 12:45 pm

Harmony Biosciences Holdings, Inc. announced the pricing of an 8 million share public offering by its shareholders at $31 per share. The company will not receive any proceeds from this sale.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 8:09 am

Harmony Biosciences (HRMY) stock fell 18.3% after announcing a public offering of up to 8 million shares by selling shareholders. The offering won't increase the company's share count, and proceeds go to the sellers. A lock-up agreement restricts insider sales for 60-90 days.

Portfolio Pulse from Henry Khederian

October 30, 2024 | 7:06 pm

Harmony Biosciences shares are declining following the announcement of a public offering of up to 8 million shares by selling shareholders Marshman Fund Trust II and Valor IV Pharma Holdings.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:47 pm

Cantor Fitzgerald has maintained an Overweight rating on Harmony Biosciences and increased the price target from $51 to $58, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 5:31 pm

Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on Harmony Biosciences and raised the price target from $56 to $59.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 3:57 pm

Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $52.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 9:46 am

Harmony Biosciences announced a public offering of up to 8 million shares of common stock by selling shareholders Marshman Fund Trust II and Valor IV Pharma Holdings. This offering does not involve the issuance of new shares by the company itself.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 9:17 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.